PURPOSE: @entity34 ( @entity34 ) has been widely used in the treatment of @entity1020 ( @entity1020 ). The complement cascade has an important role in the tissue reactions occurring after @entity34 . The @entity9346 polymorphism of the @entity4050 ( @entity4050 ) gene has been identified as a risk factor for @entity1020 . Since @entity4050 is central in the regulation of the complement system the authors wanted to analyze whether the @entity4050 @entity9346 polymorphism modifies the @entity34 outcome in @entity1020 . METHODS: A total of 88 @entity1 having been treated with @entity34 and without further scheduled @entity34 sessions were analyzed. Depending on the situation at their final @entity34 session the @entity1 were classified retrospectively as @entity34 -responders or @entity34 -nonresponders. All @entity1 were genotyped for the @entity4050 @entity9346 polymorphism. RESULTS: The proportion of @entity34 -responders was 18/26 (69.2%) in @entity1 homozygous for the @entity4050 @entity9346 risk allele, 34/50 (68.0%) in heterozygous, and 7/12 (58.3%) in @entity1 with the normal genotype (p=0.520). The median number of @entity34 treatments of the @entity34 -responders was three for all the genotypes. CONCLUSIONS: The dysfunction of the @entity4050 related to the risk of @entity1020 and caused by the @entity9346 polymorphism does not modify the outcome of @entity34 . Genotyping for @entity4050 @entity9346 cannot be used to select @entity1 for this treatment.

The effect of XXXX @entity9346 polymorphism on the outcome of photodynamic therapy in @entity1020 .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity9346 :: ('p|SUB|Y|402|H', 'ProteinMutation') :: ['Y402H'] @entity4050 :: ('3075', 'Gene') :: ['complement factor H', 'CFH'] @entity1020 :: ('MESH:D008268', 'Disease') :: ['AMD', 'age-related macular degeneration'] @entity34 :: ('MESH:D016609', 'Disease') :: ['Photodynamic therapy', 'PDT']
@entity4050 :: (3075,Gene) :: ['complement factor H']
